

CURRICULUM VITAE

Eduardo Pimenta, MD, PhD, FAHA, FESC



Home Address 27 Amaroo Avenue
Mount Colah, NSW, 2079, Australia

Business Phone/Fax +61 (0) 488 068 770 (mobile)

Email Address eduardo.pimenta@hotmail.com

Date of Birth 24th of February 1976

Languages Portuguese (native), English (fluent), Spanish (basic)

Citizenships Brazilian, Australian

Medical License Regional Medical Council (Conselho Regional de Medicina do Estado de São Paulo - Brazil) # 101417
Medical Practitioner – Medical Board of Australia – General Registration #992651

Medical Certification Brazilian Board of Cardiology, 2005
Brazilian Board of Internal Medicine – Emergency Medicine, 2005
Brazilian Board of Internal Medicine, 2004

Degrees and Diplomas Fellow of European Society of Cardiology, 2014
Ph.D., University of Queensland, Australia, 2012
Ph.D., University of Sao Paulo, Brazil, 2012
Fellow of American Heart Association, USA, 2008.
M.D., Fundação Universitaria do ABC School of Medicine, Brazil, 2000

Additional Education Leadership Oxygen, Bayer Australia & New Zealand, 2017
Leadership Strategies for Evolving Health Care Executives. Executive and Continuing Professional Education. Harvard T. HH. Chan School of Public health, 2016.
Bayer Management Program, Bayer Germany, 2016
Learn to Lead II, Bayer Australia & New Zealand, 2014
Learn to Lead I, Bayer Australia & New Zealand, 2014

CURRENT POSITIONS

2019 – present Country Medical Director, Bayer Australia/New Zealand

PREVIOUS POSITIONS

2018 – 2019 Head Medical Affairs Therapeutic Areas, Bayer Australia/New Zealand

2017 – 2018 Associate Medical Director, Bayer Australia/New Zealand

2015 - 2017 Early Clinical Leader, Experimental Medicine CV/Hem, Clinical Sciences, Drug Discovery, Bayer AG

2014 - 2015 Senior Medical Advisor - Cardiovascular, Bayer Australia & New Zealand/Regional Center of Excellence, Finerenone, Asia Pacific

2012 - 2015 Honorary Senior Fellow, University of Queensland School of Medicine

2012 - 2014 Medical Advisor, Boehringer Ingelheim Australia

2012 - 2012 Medical Registrar, General Medicine, Queensland Basic Physician Training Pathway-Southside Rotation, Queensland Health, Logan and Princess Alexandra Hospitals.

2010 - 2012 Senior Lecturer, School of Medicine – Southside Clinical School, University of Queensland, Brisbane, Australia

2010 - 2012 Principal House Officer, Hypertension Unit, Princess Alexandra Hospital, Queensland Health

2009 - 2012 Clinical Research Fellow, Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Brisbane, Australia.

2006 – 2009 Faculty, Department of Hypertension and Nephrology, Dante Pazzanese Institute of Cardiology, Sao Paulo, SP, Brazil

2006 – 2008 Post-Doctoral Research Fellow, Vascular Biology and Hypertension Program, University of Alabama at Birmingham, USA

2005 – 2006 Clinical Fellow, Department of Hypertension and Nephrology, Dante Pazzanese Institute of Cardiology, Sao Paulo, SP, Brazil

2003-2005 Advanced trainee, Cardiology, Dante Pazzanese Institute of Cardiology, Sao Paulo, SP, Brazil

2002-2006 Instructor for Advanced Cardiac Life Support (ACLS) training, American Heart Association, within Brazilian Cardiology Society

2001-2003 Internal Medicine Residency, ABC School of Medicine, Santo Andre, SP, Brazil

AWARDS (descending chronological order)

1. Author of most read article until 2016 published in the Revista Factores de Risco (Risk Factors Journal), digital format, Portuguese Society of Cardiology, Lisbon, Portugal, 2017.
2. Best Oral Presentation, 8th Asian-Pacific Hypertension Congress of Hypertension, Taipei, Taiwan, 2011.
3. Young Investigator Award, 8th Asian-Pacific Hypertension Congress of Hypertension, Taipei, Taiwan, 2011.
4. Runner Up, Clinical Researcher Award 2011, Queensland Health and Medical Research Awards, Australian Society for Medical Research, Brisbane, Australia, 2011.
5. *Young Career Investigator Oral Award, High Blood Pressure Research Council of Australia, Australia, 2010.
6. Nominee to British Hypertension Society, High Blood Pressure Research Council of Australia, Australia, 2010.

7. *Top paper published in *Hypertension* in 2009 - Category Clinical Science, American Heart Association, Washington, D.C., U.S.A., 2010.
8. Young Clinician Investigator of the Year Award, Princess Alexandra Hospital, Brisbane, Queensland, Australia, 2010.
9. Travel Scholarship, International Society of Hypertension Satellite Meeting – The Pathogenesis of Essential Hypertension, Baker IDI Heart and Diabetes Institute, Australia, 2010.
10. Finalist, Early Career Investigator Poster Award, High Blood Pressure Research Council of Australia, Australia, 2009.
11. Finalist, Early Career Investigator Oral Award, High Blood Pressure Research Council of Australia, Australia, 2009.
12. Young Clinician Investigator of the Year Award, Princess Alexandra Hospital, Brisbane, Queensland, Australia, 2009.
13. *Young Clinician Scientist Award, International Academy of Cardiovascular Sciences - North America Chapter, U.S.A., 2008.
14. Trainee Research Award Winner, Southern Section – American Federation for Medical Research/Southern Society for Clinical Investigation, U.S.A., 2008.
15. Finalist, Dirceu Vieira dos Santos Filho Award, Brazilian Cardiology Society, Brazil, 2007.
16. *Joseph Reeves Award for Excellence in Research by a Post-Doctoral Scholar, University of Alabama at Birmingham, U.S.A., 2007.
17. 3rd Place. Young Clinician Scientist Award, International Academy of Cardiovascular Sciences - North America Chapter, U.S.A., 2007.
18. Trainee Research Award Winner, Southern Section – American Federation for Medical Research/Southern Society for Clinical Investigation, U.S.A., 2007.
19. Brazilian Archives of Cardiology Best Scientific Publication Award, Brazilian Cardiology Society, Brazil, 2006.
20. Best medical poster, XXVI Medical Congress of ABC School of Medicine, Brazil, 2001.
21. 3rd Place. Best scientific movie, XIII Medical Congress of ABC School of Medicine, Brazil, 1998.

LEADERSHIP POSITIONS

- | | |
|-----------|---|
| 2013-2014 | Vice President Australian Pharmaceutical Physicians Association |
| 2011-2012 | Clinical Liaison, Executive Committee, High Blood Pressure Research Council of Australia. |
| 2003-2005 | President, Association of Medical Residents, Dante Pazzanese Institute of Cardiology. |
| 2001-2002 | Chief Resident, Department of Medicine, ABC School of Medicine. |
| 1996-1997 | Treasurer, “Nylceo Marques de Castro” University Athletic Association, ABC School of Medicine. |
| 1995-1997 | Director, Men’s Handball, “Nylceo Marques de Castro” University Athletic Association, ABC School of Medicine. |

CONFERENCE ORGANIZING EXPERIENCE

1. 24th Meeting of the International Society of Hypertension, Sydney, Australia, September/October 2012, Member of Scientific Advising Committee.
2. Aldosterone & Salt: Heart and Kidney, Satellite Symposium for the 24th Meeting of the International Society of Hypertension, Palm Cove, Australia, October 2012, Member of Organizing Committee.
3. 3rd International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia, and Diabetes Mellitus – the Role of Fixed Combination Therapy in the Reduction of Global Cardiovascular Risk, Brisbane, Australia, November 2010, Member of the Local Organizing Committee.
4. XVIIIth Scientific Sessions of Inter-American Society of Hypertension, Belo Horizonte, Brazil, August 2009, Member of the Scientific Program Committee.

5. Portugal-Brazil Symposium of Hypertension, Pocone, Brazil, June 2008, Member of the Executive Committee.

EDITORIAL BOARD

- 2014-2017 Section Editor, Topical Collection on Resistant Hypertension, Current Hypertension Reports.
2008-2009 Editor, website of Department of Hypertension, Brazilian Cardiology Society.
2008-2009 Co-Editor, Brief Communications Section, Revista Brasileira de Hipertensão (Brazilian Journal of Hypertension).

INVITED REVIEWER

1. * American Journal of Hypertension
2. * American Journal of Kidney Diseases
3. Annals of Long-Term Care: Clinical Care and Aging
4. Arquivos Brasileiros de Cardiologia (Brazilian Archives of Cardiology)
5. Cardiology
6. *Chest
7. * Circulation
8. Clinical Medicine – Cardiology
9. Clinical Medicine – Therapeutics
10. European Journal of Clinical Investigations
11. Expert Review of Clinical Pharmacology
12. Future Drugs
13. * Hypertension
14. * Hypertension Research
15. Integrated Blood Pressure Control
16. Journal of Clinical Hypertension
17. Journal of Hypertension
18. Journal of Human Hypertension
19. * The Lancet
20. PIER – Physicians’ Information and Education Resource
21. Therapeutic Advances in Chronic Disease
22. Vascular Health and Risk Management

RESEARCH GRANTS AWARDED

1. **Pimenta E.** Effect of adrenalectomy and spironolactone in the severity of obstructive sleep apnoea in patients with primary aldosteronism. Princess Alexandra Research Foundation 2011-2012. \$75,000.

GRANT ASSESSMENT

I have reviewed a major grant application (over \$3 million AUD) for the Wellcome Trust (UK).

BOOK CHAPTERS (descending chronological order)

1. **Pimenta E**, Oparil S. Epidemiology of Hypertension. In: Saha SA (ed). Current Advances in Cardiovascular Risk. New York: Nova Science Publishers, Inc., 2012:45-54. ISDN/ISBN: 978-1-62081-746-9.
2. **Pimenta E**, Passarelli Jr O. Medical treatment of hypertension: resistant hypertension. In: Brandao A, Amodeo C, Nobre F (eds). Hypertension. 2nd edition. Rio de Janeiro, Brazil: Elsevier, 2012:335-340 (*in portuguese*). ISDN/ISBN: 978-85-352-5325-2.
3. * **Pimenta E**, Calhoun DA, Oparil S. Hypertensive emergencies. In: Brown DL, Jeremias A (eds). Cardiac Intensive Care. 2nd edition. Philadelphia: Elsevier, 2010:355-367. ISDN/ISBN: 9781416037.
4. **Pimenta E**, Oparil S. Hypertension in Women (Hipertensión en la mujer). In: Esper R (ed). Textbook of Vascular Mechanisms and Hypertension (Tratado De Mecánica Vascular e Hipertensión Arterial). Buenos Aires, Argentina: Inter-Médica S.A.I.C.I., 2010:679-686 (*in spanish*). ISDN/ISBN: 9789505553846.
5. * **Pimenta E**, Calhoun DA. The optimal management of patients with resistant hypertension due to aldosterone excess. In: Weir MR (ed). Evidence-based Management of Hypertension. Shrewsbury: TFM Publishing Ltd, 2010:69-82. ISDN/ISBN: 9781903378724.
6. * **Pimenta E**, Oparil S. JNC7 and ALLHAT: Guidelines/Changes in American and European Guidelines. In: Hollenberg NK, Braunwald E (eds). Atlas of Hypertension. 6th edition. Philadelphia: Current Medicine Group LLC, 2009:321-327. ISDN/ISBN: 9781573403085.
7. * **Pimenta E**, Calhoun DA, Oparil S. Etiology and pathogenesis of systemic hypertension. In: Crawford MH, DiMarco JP, Paulus WJ (eds). Cardiology. 3rd edition. Philadelphia: Elsevier, 2009:511-522. ISDN/ISBN: 9780723434856.
8. Passarelli Jr O, Amodeo C, **Pimenta E**. Risk factors for coronary artery disease: metabolic syndrome In: Ferreira C, Povia R (eds). Clinical cardiology. 1st edition. São Paulo: Atheneu, 2009:311-321(*in portuguese*). ISDN/ISBN: 9788538800385.
9. **Pimenta E**, Ramos RF. Acute coronary syndromes and hypertension. In: Passarelli Jr O, Povia R, Martin JFV, Consolim-Colombo FM (eds). Hypertensive emergencies in the Clinical Practice. 1st edition. São Paulo: Segmento Farma, 2009:103-109(*in portuguese*). ISDN/ISBN: 9788598353944.
10. **Pimenta E**, Consolim-Colombo FM. Pathophysiology of hypertensive emergencies. In: Passarelli Jr O, Povia R, Martin JFV, Consolim-Colombo FM (eds). Hypertensive emergencies in the Clinical Practice. 1st edition. São Paulo: Segmento Farma, 2009:45-51(*in portuguese*). ISDN/ISBN: 9788598353944.
11. **Pimenta E**, Sousa MG, Passarelli Jr O. Therapeutics: pharmacologic strategies. In: Passarelli Jr O, Fonseca FAH, Colombo FMC, Scala LCN, Povia R(eds). Difficult to control hypertension: from theory to practice. 1st edition. São Paulo: Segmento Farma, 2008:278-287(*in portuguese*). ISDN/ISBN: 9788598353807.
12. **Pimenta E**, Passarelli Jr O. Secondary causes of hypertension: primary hyperaldosteronism. In: Passarelli Jr O, Fonseca FAH, Colombo FMC, Scala LCN, Povia R(eds). Difficult to control hypertension: from theory to practice. 1st edition. São Paulo: Segmento Farma, 2008:151-159(*in portuguese*). ISDN/ISBN: 9788598353807.
13. Borelli F, **Pimenta E**. Secondary causes of hypertension: renovascular hypertension. In: Passarelli Jr O, Fonseca FAH, Colombo FMC, Scala LCN, Povia R(eds). Difficult to control hypertension: from theory to practice. 1st edition. Sao Paulo: Segmento Farma, 2008:137-147(*in portuguese*). ISDN/ISBN: 9788598353807.
14. * **Pimenta E**, Oparil S. Gender and blood pressure. In: Izzo Jr JL, Sica D, Black HR (eds). Hypertension Primer. 4th edition. Baltimore: Lippincott, Williams & Wilkins, 2008:269-273. ISDN/ISBN: 9780781782050.
15. Gonzaga CC, **Pimenta E**, Sousa MG, Passarelli Jr O. Antihypertensive combination therapy: current approach. In: Serrano CV Jr., Sobral Filho DC (eds). How to treat: hypertension. 1st edition. Barueri, SP: Manole, 2008:83-97(*in portuguese*).
16. **Pimenta E**, Calhoun DA. Drug treatment. In: Póvia R(ed). Hypertension in clinical practice. 1st edition. São Paulo: Atheneu, 2007:337-348(*in portuguese*).

17. **Pimenta E**, Passarelli Jr O. Metabolic syndrome. In: Póvoa R(ed). Hypertension in clinical practice. 1st edition. São Paulo: Atheneu, 2007:177-186(*in portuguese*).
18. Kovacs C, Stefanuto A, D'Alfonso GV, Amparo FC, Passarelli Jr O, **Pimenta E**. Metabolic syndrome. In: Magnoni D, Stefanuto A, Kovacs C (eds). Clinical nutrition in cardiology. 1st edition. São Paulo: Sarvier, 2007:193-208(*in portuguese*). ISDN/ISBN: 85-7378-167-X.
19. Carlucci FM, Borelli F, **Pimenta E**. Hypertension. In: Magnoni D, Stefanuto A, Kovacs C (eds). Clinical nutrition in cardiology. 1st edition. São Paulo: Servier, 2007:127-136(*in portuguese*). ISDN/ISBN: 85-7378-167-X.
20. Passarelli Jr O, **Pimenta E**. Renin inhibitors. In: Fonseca FAH(ed). Cardiovascular disease: Clinical Management. 1st edition. São Paulo: Planmark, 2006:45-47(*in portuguese*).
21. Dioguardi G, **Pimenta E**, Borelli F, Passarelli Jr O. Hypertension, exercise and sport practice. In: Ghorayeb N, Dioguardi G (eds). Exercise and Sport Cardiology Textbook. 1st edition. São Paulo: Atheneu, 2006:349-356(*in portuguese*).

PUBLICATIONS (descending chronological order)

1. Wolley MJ, **Pimenta E**, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. *J Hum Hypertens* 2017;31:561-567. Doi: 10.1038/jhh.2017.28.
2. **Pimenta E**, Jensen M, Jung D, Schaumann F, Boxnick S, Truebel H. Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study. *J Clin Med Res*. 2016;8(11):836-9. doi: <http://dx.doi.org/10.14740/jocmr2738w>.
3. **Pimenta E**, Calhoun DA. Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension? *Curr Hypertens Rep*. 2016 Apr;18(4):25. doi: 10.1007/s11906-016-0634-9.
4. Wang JG, **Pimenta E**, Chwallek F. Comparative review of blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril. *Vasc Health Risk Manag* 2014;10:189-200.
5. Wolley M, Gordon RD, **Pimenta E**, Daunt N, Slater GJ, Ahmed AH, Stowasser M. Repeating adrenal vein sampling when neither aldosterone/cortisol ratio exceeds peripheral yields a high incidence of aldosterone-producing adenoma. *J Hypertens* 2013;31(10):2005-9. doi: 10.1097/HJH.0b013e328362add3.
6. **Pimenta E**, Calhoun DA. Response to “Obstructive sleep apnea and sodium intake: what is the mechanism?”. *Chest* 2013;144(2):720. doi: 10.1378/chest.13-0969.
7. Vilela-Martin JF, Vaz-de-Melo RO, Cosenso-Martin LN, Kuniyoshi CH, Yugar-Toledo JC, Pinhel MA, Souza GF, Souza DR, **Pimenta E**, Moreno Junior H, Cipullo JP. Renin Angiotensin System Blockage associates with Insertion/Deletion Polymorphism of Angiotensin Converting Enzyme in Patients with Hypertensive Emergency. *DNA Cell Biol* 2013;32(9):1-8. doi: 10.1089/dna.2012.1951.
8. Chao CT, Wu VC, Kuo CC, Lin YH, Chang CC, Chueh SJ, Wu KD, **Pimenta E**, Stowasser M. Diagnosis and management of primary aldosteronism. *Ann Med*. 2013;45(4):375-83. doi: 10.3109/07853890.2013.785234.
9. ***Pimenta E**, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. *Chest* 2013;143(4):978-983. doi: 10.1378/chest.12-0802.
10. **Pimenta E**, Stowasser M, Gordon RD. Salt, aldosterone and hypertension. *J Hum Hypertens* 2013;27(1):1-6. doi: 10.1038/jhh.2012.27.
11. **Pimenta E**, Wolley M, Stowasser M. Adverse cardiovascular outcomes of corticosteroid excess. *Endocrinology* 2012;153(11):5137-5142. doi:10.1210/en.2012-1573.
12. de Souza WS, Alessi A, Cordeiro A, da Rocha Nogueira A, Feitosa A, Amodeo C, Rodrigues C, Calhoun D, Barbosa E, **Pimenta E**, Muxfeldt E, Consolin-Colombo F, Salles G, Rosito G, Moreno H Jr, Martin JF, Yugar JC, Bortolotto L, Scala LC, de Souza M, Gomes MA, Malachias MB, Gus M, Passarelli O Jr, Jardim PC, Toscano PR, Sanchez R, Miranda RD, Póvoa R, Weimar KS, Andrea AB. First Brazilian position on resistant hypertension. *Arq Bras Cardiol* 2012;99(1):576-585. doi: 10.1590/S0066.

13. Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, **Pimenta E**, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J Jr, Wu KD, Wu VC, Pessina AC. The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. *J Clin Endocrinol Metab* 2012;97:1606-1614. doi: 10.1210/jc.2011-2830.
14. **Pimenta E**, Oparil S. Renal Sympathetic Denervation for Treatment of Hypertension. *Curr Treat Options Cardiovasc Med* 2012;14(2):127-135. doi: 10.1007/s11936-012-0166-9.
15. **Pimenta E**, Calhoun DA. Hypertensive crisis: forget the numbers. *J Hypertens* 2012;30(5):882-883. doi: 10.1097/HJH.0b013e328352ea35.
16. **Pimenta E**, Oparil S. Management of hypertension in the elderly. *Nat Rev Cardiol* 2012;9(5):286-296. doi: 10.1038/nrcardio.2012.27.
17. ***Pimenta E**, Calhoun DA. Resistant hypertension: incidence, prevalence and prognosis. *Circulation* 2012;125(13):1594-6. doi: 10.1161/CIRCULATIONAHA.112.097345.
18. Stowasser M, Ahmed AH, **Pimenta E**, Taylor P, Gordon RD. Factors affecting the aldosterone/renin ratio. *Horm Metab Res* 2012 Mar;44(3):170-6. doi: 10.1055/s-0031-1295460.
19. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin, JFV, Demacq C, **Pimenta E**, Calhoun DA, Moreno Junior H. Non-dipping pattern relates to endothelial function in patients with uncontrolled hypertension. *J Hum Hypertens* 2011;25(11):656-664. doi: 10.1038/jhh.2011.43.
20. **Pimenta E**. Hypertension in women. *Hypertens Res* 2012;35:148-152. doi:10.1038/hr.2011.190.
21. **Pimenta E**, Gordon RD, Daunt N, Slater G, Stowasser M. Hyperreninemic hypertension following presumed abdominal trauma. *Nat Rev Nephrol* 2011;7:730-734. doi: 10.1038/nrneph.2011.127.
22. Ahmed AH, Gordon RD, Sukor N, **Pimenta E**, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. *J Clin Endocrinol Metab* 2011;96(9): 2904-2911. doi: 10.1210/jc.2011-0138.
23. Baumann BM, Cline DM, **Pimenta E**. Treatment of hypertension in the emergency department. *J Am Soc Hypertens* 2011;5(5):366-377. doi:10.1016/j.jash.2011.05.002.
24. ***Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, Stowasser M. Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma. *J Hum Hypertens* 2011;25(10):592-599. doi:10.1038/jhh.2010.102.
25. **Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, Stowasser M. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case control study. *J Clin Endocrinol Metab* 2011;96(9):2813-2820. doi: 10.1210/jc.2011-0354.
26. Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, **Pimenta E**, Calhoun DA, Moreno Junior H. Gene Variation in Resistant Hypertension: Multilocus Analysis of the Angiotensin 1-Converting Enzyme, Angiotensinogen, and Endothelial Nitric Oxide Synthase Genes. *DNA Cell Biol* 2011;30(8):555-564. doi:10.1089/dna.2010.1156.
27. **Pimenta E**. Update on Diagnosis and Treatment of Resistant Hypertension. *Iran J Kidney Dis* 2011;5:215-227.
28. Ahmed AH, Gordon RD, Taylor P, Ward G, **Pimenta E**, Stowasser M. Effect of Contraceptives on Aldosterone/Renin Ratio May Vary According to the Components of Contraceptive, Renin Assay Method, and Possibly Route of Administration. *J Clin Endocrinol Metab* 2011;96(6):1797-1804. doi: 10.1210/jc.2010-2918.
29. **Pimenta E**, Stowasser M. What is new in the management of resistant hypertension? *Therapy* 2011;8(3):261-273. doi: 10.2217/THY.11.14.
30. Stowasser M, **Pimenta E**, Gordon RD. Familial or Genetic Primary Aldosteronism and Gordon's Syndrome. *Endocrinol Metab Clin North Am* 2011;40(2):343-368. doi:10.1016/j.ecl.2011.01.007.

31. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin, JFV, Demacq C, **Pimenta E**, Calhoun DA, Moreno Junior H. Characteristics of resistant hypertension: aging, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. *J Hum Hypertens* 2011;25:532-538. doi: 10.1038/jhh.2010.95.
32. Ahmed AH, Calvird M, Gordon RD, Taylor P, Ward G, **Pimenta E**, Stowasser M. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. *J Clin Endocrinol Metab* 2011;96:1039-1045. doi:10.1210/jc.2010-2603.
33. Ahmed AH, Gordon RD, Taylor P, Ward G, **Pimenta E**, Stowasser M. Are women more at risk of false positive primary aldosteronism screening and unnecessary suppression testing than men? *J Clin Endocrinol Metab* 2011;96:E340-E346. doi:10.1210/jc.2010-1355.
34. Acelajado MC, **Pimenta E**, Calhoun DA. Salt and aldosterone: a concert of bad effects. *Hypertension* 2010;56:804-805. doi: 10.1161/HYPERTENSIONAHA.110.160960.
35. **Pimenta E**, Oparil S. Impact of Olmesartan on blood pressure, endothelial function and cardiovascular outcomes. *Integrated Blood Pressure Control* 2010;3:113-123. doi: 10.2147/IBPC.S11717.
36. **Pimenta E**, Calhoun DA. Treatment of resistant hypertension. *J Hypertens* 2010;28:2194-2195. doi: 10.1097/HJH.0b013e32833eafa3.
37. **Pimenta E**. Should we send our kids to the gym? *Hypertens Res.* 2010;33:880-882. doi: 10.1038/hr.2010.118.
38. Gonzaga CC, Gaddam KK, Ahmed MI, **Pimenta E**, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. *J Clin Sleep Med* 2010;6(4):363-368.
39. Gaddam KK, **Pimenta E**, Harding S, Thomas SJ, Cofield SS, Oparil S, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnea in patients with resistant hypertension: a preliminary report. *J Hum Hypertens* 2010;24:532-537. doi: 10.1038/jhh.2009.96.
40. Ahmed AH, Gordon RD, Taylor P, Ward G, **Pimenta E**, Stowasser M. Effect of atenolol on aldosterone/renin ratio calculated by both plasma renin activity and direct renin concentration in healthy male volunteers. *J Clin Endocrinol Metab* 2010;95:3201-3206. doi: 10.1210/jc.2010-0225.
41. **Pimenta E**. Is There a Place on the Shelf for Aliskiren? *Curr Cardio Risk Rep* 2010;4:264-270. doi: 10.1007/s12170-010-0108-6.
42. **Pimenta E**, Calhoun DA. Effects of dietary sodium reduction on blood pressure in patients with resistant hypertension. *The Asia-Pacific Journal of Cardiology* 02 June 2010 <http://www.slm-asia.com/the-asia-pacific-journal-of-cardiology/details/article/effects-of-dietary-sodium-reduction-on-blood-pressure-in-patients-with-resistant-hypertension/>
43. Stowasser M, Taylor PJ, **Pimenta E**, Ahmed AH, Gordon RD. Laboratory investigation of primary aldosteronism. *Clin Biochem Rev* 2010;31(2):39-56.
44. VI Brazilian Guidelines of Hypertension. *Arq Bras Cardiol* 2010;95(1 Suppl):1-51.
45. **Pimenta E**. Increasing adherence: is that enough? *Hypertens Res.* 2010;33:411-413. doi:10.1038/hr.2010.33.
46. *Gaddam KK, Corros C, **Pimenta E**, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. *Hypertension* 2010;55(5):1137-1142. doi: 10.1161/HYPERTENSIONAHA.109.141531.
47. **Pimenta E**, Calhoun DA. Response to "Effective" Plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. *Hypertension* 2010;55:e17. doi: 10.1161/HYPERTENSIONAHA.109.148296.
48. ***Pimenta E**, Oparil S. Prehypertension. *Nat Rev Nephrol* 2010;6(1):21-30. doi: 10.1038/nrneph.2009.191.
49. Oparil S, **Pimenta E**. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or gender. *J Clin Hypertens* 2010;12(1):3-13. doi: 10.1111/j.1751-7176.2009.00217.x.

50. Sousa MG, **Pimenta E**, Borelli FAO. Medical association and interaction in hypertension treatment – fixed combinations. *Rev Bras Hipertens* 2009;16(4):236-241 (in portuguese).
51. **Pimenta E**. Single Sevikar(R): combination therapy for the treatment of hypertension. *Clinical Medicine: Therapeutics* 2009;1:703-709.
52. **Pimenta E**, Stowasser M. Uncontrolled hypertension: beyond pharmacological treatment. *Hypertens Res* 2009;32(9):729-731. doi:10.1038/hr.2009.108.
53. ***Pimenta E**, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia L, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. *Hypertension* 2009;54(3):475-481. doi: 10.1161/HYPERTENSIONAHA.109.131235.
54. **Pimenta E**, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. *Ther Clin Risk Manag* 2009;5(3):459-464.
55. Ubaid-Girioli S, Souza LA, Yugar-Toledo JC, LC Martins, Ferreira-Melo S, Coelho OR, Sierra C, Coca A, **Pimenta E**, Moreno H. Aldosterone excess or escape: treating resistant hypertension. *J Clin Hypertens* 2009;11(5):245-252. doi: 10.1111/j.1751-7176.2009.00110.x.
56. **Pimenta E**, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. *Vasc Health Risk Manag* 2009;5(1):453-463.
57. ***Pimenta E**, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. *Hypertension* 2009;53:585-586. doi: 10.1161/HYPERTENSIONAHA.108.123406.
58. **Pimenta E**. Olmesartan/amlodipine: a combination therapy for the treatment of hypertension. *Adv Ther* 2009;26(1):1-11. doi: 10.1007/s12325-008-0132-9.
59. ***Pimenta E**, Calhoun DA, Oparil S. Sleep apnea, aldosterone and resistant hypertension. *Prog Cardiovasc Dis* 2009;51(5):371-380. doi: 10.1016/j.pcad.2008.02.004.
60. *Gaddam KK, **Pimenta E**, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. *Curr Probl Cardiol* 2009;34(2):51-84. doi:10.1016/j.cpcardiol.2008.10.002.
61. Borelli FA, Sousa MG, Passarelli Jr. O, **Pimenta E**, Gonzaga C, Cordeiro L, Lotaif L, Amodeo C. Hypertension in old age: importance of treatment. *Rev Bras Hipertens* 2008;15(4):236-239 (in portuguese).
62. **Pimenta E**, Amodeo C, Oparil S. Hypertension in Women. *Int J Atheroscler* 2008;3(3):138-145.
63. **Pimenta E**. Hydrochlorothiazide vs. chlorthalidone: all thiazides are the same. *Rev Bras Hipertens* 2008;15(3):166-167 (in portuguese).
64. Fedlman A, Freitas LZ, Collet CA, Mota AR, **Pimenta E**, Sousa MG, Codeiro AC, Passarelli Jr O, Borelli FA, Amodeo C. Interrelation among renal artery stenosis, hypertension and chronic renal failure. *Rev Bras Hipertens* 2008;15(3):181-184 (in portuguese).
65. **Pimenta E**, Oparil S. Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: American perspective. *Pol Arch Med Wewn* 2008 Sep;118(9):508-12.
66. **Pimenta E**, Oparil S. Renin Inhibitors: Novel Agents for Renoprotection or a Better Angiotensin Receptor Blocker for Blood Pressure Lowering? *Cardiol Clin* 2008;26:527-535. doi: 10.1016/j.ccl.2008.06.003.
67. **Pimenta E**, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. *Vasc Health Risk Manag* 2008;4(3):653-664.
68. Borelli FA, **Pimenta E**. Secondary hypertension – renovascular hypertension: diagnosis and treatment. *Rev Soc Cardiol Estado de São Paulo* 2008;2:135-140 (in portuguese).
69. **Pimenta E**. Mechanisms of left ventricular hypertrophy. *Rev Bras Hipertens* 2008;15(2):111-116 (in portuguese).

70. Moreira HG, Sette JB, Keiralla LC, Alves SG, **Pimenta E**, Sousa MG, Cordeiro AC, Passarelli Jr O, Borelli FA, Amodeo C. Diabetes, hypertension and chronic kidney disease: treatment strategies and their limitations. *Rev Bras Hipertens* 2008;15(2):111-116 (in portuguese).
71. Amodeo C, Passarelli Jr. O, **Pimenta E**. Hypertension in the metabolic syndrome: a disease of modern civilization. *Panorama Cardiometabolico* 2008;5:16-25(in portuguese).
72. *Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, **Pimenta E**, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone and persistent intravascular volume expansion. *Arch Intern Med* 2008;168(11):1159-1164. doi: 10.1001/archinte.168.11.1159.
73. ***Pimenta E**, Oparil S. Beyond brachial pressure effect. *Curr Hypertens Rep* 2008;10(3):213-215.
74. **Pimenta E**. Benefits of antihypertensive treatment with angiotensin receptor blockers. *Cardiometabolismo na Pratica Clinica* 2008;2:20-22(in portuguese).
75. Santos I, Maia J, Cardoso E, Almiro JF, Braga J, **Pimenta E**, Sousa MG, Passarelli Jr O, Borelli FA, Amodeo C. Patient with hypertension and high cardiovascular risk. *Kardia* 2008;9:9-12 (in portuguese).
76. **Pimenta E**. Hypertension: from sphygmomanometer to reduction of cardiovascular risk. *Cardiometabolismo na Pratica Clinica* 2008;2:6-11(in portuguese).
77. ***Pimenta E**, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. *J Clin Hypertens* 2008;10(3):239-244. doi: .1111/j.1751-7176.2008.08143.x.
78. ***Pimenta E**, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. *Hypertension* 2008;51:339-344. doi: 10.1161/HYPERTENSIONAHA.107.100701.
79. ***Pimenta E**, Calhoun DA. Resistant hypertension and aldosteronism. *Curr Hypertens Rep* 2007;9:353-359.
80. **Pimenta E**. Resistant hypertension and hyperaldosteronism. *Rev Fac Cienc Med Sorocaba* 2007;9(3):1-3(in portuguese).
81. **Pimenta E**, Calhoun DA. Aldosterone receptor blockers and resistant hypertension. *Rev Bras Hipertens* 2007;14(3):184-185(in portuguese).
82. ***Pimenta E**, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-hr blood pressure control. *J Hypertens* 2007;25(10):2131-2137. doi: 10.1097/HJH.0b013e3282a9be30.
83. **Pimenta E**, Calhoun DA. Hypertension and hyperaldosteronism: a common association. *Rev Bras Hipertens* 2007;14(2):116-117(in portuguese).
84. **Pimenta E**, Calhoun DA. Evaluation and treatment of resistant hypertension. *Rev Bras Hipertens* 2007;14(2):71-78.
85. **Pimenta E**, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. *Arq Bras Cardiol* 2007;88(6):683-692. doi: 10.1590/S0066-782X2007000600009.
86. **Pimenta E**, Passarelli Jr O, Borelli F, Sousa MG, Gun C, Amato V, Amodeo C, Piegas L. Metabolic syndrome in patients undergoing coronary artery bypass graft: prevalence and a marker of morbidity/mortality during hospitalization and 30 days after hospital discharge. *Arq Bras Cardiol* 2007;88(4):413-417. doi: 10.1590/S0066-782X2007000400008.
87. ***Pimenta E**, Calhoun DA. Primary aldosteronism: diagnosis and treatment. *J Clin Hypertens* 2006;8(12):887-893. doi: 10.1111/j.1524-6175.2006.06107.x.
88. ***Pimenta E**, Calhoun DA. Aldosterone, Dietary Salt, and Renal Disease. *Hypertension* 2006;48:209-210. doi: 10.1161/01.HYP.0000230482.82239.a0.
89. **Pimenta E**, Ramos RF, Gun C, Santos ES, Timerman A, Piegas LS. Renal Function Development During Acute Phase of Myocardial Infarction as Prognostic Factor in In-Hospital and One Year Outcomes. *Arq Bras Cardiol* 2006;83:170-174. doi: 10.1590/S0066-782X2006000300003.
90. Passarelli Jr O, Borelli FA, Sousa MG, **Pimenta E**, Borelli FA, Amodeo C. Metabolic Syndrome. *Rev Bras Clin Terap* 2006;32(1):4-10(in portuguese).

91. **Pimenta E**, Passarelli Jr. O. Prehypertension and cardiovascular risk. *Kardia* 2006;9(2):14-16(*in portuguese*).
92. Barros MS, Carvalho RS, Santiago TM, Silva TO, Zambrano MV, Gutierrez SA, D'avilla E, Borelli FA, Passarelli Jr O, Sousa MG, **Pimenta E**, Amodeo C. When should we investigate pheochromocytoma? *Rev Bras Hipertens* 2006;13(3):231-234(*in portuguese*).
93. **Pimenta E**. Abdominal circumference: simple method for stratification of cardiovascular risk. *Kardia* 2006;9(1):13-14(*in portuguese*).
94. Braga J, Almiro JF, Santos I, Maia J, Cardoso E, **Pimenta E**, Sousa MG, Passarelli Jr O, Borelli FA, Amodeo C. Leriche's Syndrome as cause of renovascular hypertension. *Rev Bras Hipertens* 2005;13(1):75-78(*in portuguese*).
95. **Pimenta E**, Passarelli Jr. O, Borelli FA, Sousa MG, Amodeo C. Practical aspects in hypertensive urgencies and emergencies. *Medico Reporter* 2005;66:36-38(*in portuguese*).
96. Fagundes Jr AAP, **Pimenta E**, Pucinelli M, Borelli FAO, Passarelli Jr O, Sousa GM, Amodeo C. Takayasu's arteritis – knowledge for diagnosis. *J Bras Nefrol* 2005;27(4):215-219(*in portuguese*).
97. Valdigem BP, Procópio AGM, Guerra DM, Freitas CM, Belzarez OEG, Lopez PRA, **Pimenta E**, Sousa MG, Passarelli Jr. O, Borelli FA, Amodeo C. Contrast induced nephropathy: a reality in patients submitted to invasive tests. *Rev Bras Hipertens* 2005;12(4):276-278(*in portuguese*).
98. **Pimenta E**, Amodeo C. Antihypertensive treatment and endothelial function. *Kardia* 2005;8(3):16-18(*in portuguese*).
99. Cunha Jr MA, Verzola ACA, Brito LA, Wambier LA, Vilela AA, Castelo GAC, **Pimenta E**, Borelli FA, Passarelli Jr O, Sousa GM, Amodeo C. Systemic atherosclerotic disease – diagnosis and treatment. *Rev Bras Hipertens* 2005;12(3):206-209(*in portuguese*).
100. Gonzaga CC, Perez Hervaz HE, Flato UAP, Salles VAA, Pinto VBC, **Pimenta E**, Borelli FAO, Passarelli Jr O, Sousa GM, Amodeo C. Ambulatory blood pressure monitoring role in the diagnosis and treatment of arterial hypertension *Rev Bras Hipertens* 2005;12(2):134-136(*in portuguese*).
101. Santos LF, Thomazi MC, **Pimenta E**, Silva NJ, Bussadori PF, Passos RL, Garcia VG, Sousa MG, Passarelli Jr O, Borelli FA, Amodeo C, Lima JP, Grimberg R, Armaganijan LV, Janczuk D, Villakuiran CV. Secondary hypertension - pheochromocytoma. *Rev Bras Hipertens* 2005;12(1):61-65(*in portuguese*).
102. **Pimenta E**, Borelli C, Passarelli Jr O, Sousa M, Amodeo C. Renovascular hypertension in a patient with solitary kidney. *Rev Bras Hipertens* 2004;11(1):76-78(*in portuguese*).
103. **Pimenta E**, Amodeo C. Hypertension and Endothelium. *Continued Medical Educational Program of The Brazilian Cardiology Society* 2004;3(1-7):17-18(*in portuguese*).
104. **Pimenta E**, Mesquita C, Yamaguchi D, Peixoto D, Sandoval F, Borelli FA, Passarelli Jr. O, Amodeo C. “Renovascular hypertension in a patients with solitary kidney”, *Rev Bras Hipertens* 2004;11(1):76-78(*in portuguese*).
105. Amodeo C, **Pimenta E**. Hypertension and endothelium. *Kardia* 2003;6(3):12-14(*in portuguese*).
106. **Pimenta E**, Anti SMA. Hemarthrosis of the Knees Following Streptokinase Therapy for Acute Myocardial Infarction. *Arq Bras Cardiol* 2003;80(6):639-640. doi: 10.1590/S0066-782X2003000600007.

ABSTRACTS PRESENTED IN SCIENTIFIC MEETINGS (descending chronological order)

1. **Pimenta E**, Jensen M, Jung D, Lobmeyer M, Schmitt W, Schaumann F, Boxnick S, Truebel H. A novel balanced dual vasopressin V1a/V2 receptor antagonist for treatment of congestive heart failure: results from a first-in-man study. *Circulation* 2017;136 (Suppl 1):A15196.
2. Ahmed AH, Gordon RD, **Pimenta E**, Taylor PJ, Stowasser M. A need to re-focus on precision of screening and diagnostic tests in primary aldosteronism. *J Hypertens* 2012;30(eSuppl 1):e182. doi: 10.1097/01.hjh.0000420643.66450.df.
3. Hargreaves K, **Pimenta E**, Smith E. Factors related to lack of blood pressure control among patients treated with angiotensin receptor blockers. *J Hypertens* 2012;30(eSuppl 1):e142. doi: 10.1097/01.hjh.0000420364.69420.9f.

4. Wolley M, Gordon R, **Pimenta E**, Daunt N, Slater G, Ku K, Estella E, Storie WJ, Nikwan N, Stowasser M. Repeat adrenal vein sampling when neither aldosterone/cortisol ratio exceeds peripheral yields a high incidence of aldosterone-producing adenoma. *J Hypertens* 2012;30(eSuppl 1):e133. doi: 10.1097/01.hjh.0000420307.20519.bb.
5. **Pimenta E**, Calhoun DA, Gordon RD, Kennedy D, Tolhurst S, Cowley D, Stowasser M. Obstructive sleep apnea is prevalent in primary aldosteronism: 3D magnetic resonance imaging to study improvement with aldosterone blockade – preliminary findings. *J Hypertens* 2012;30(eSuppl 1):e18. doi: 10.1097/01.hjh.0000419883.25711.0b.
6. **Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, Stowasser M. Aldosterone excess stimulates salt appetite in patients with aldosterone producing adenoma. *J Hypertens* 2011;29(Suppl B):e1. doi: 10.1097/01.hjh.0000407980.89443.13.
7. **Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, Stowasser M. Aldosterone reduction by unilateral adrenalectomy reduces salt appetite in patients cured of primary aldosteronism. *J Hypertens* 2011;29(Suppl A):e65.
8. **Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, Stowasser M. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism, but not in patients with essential hypertension. *Hypertension* 2011;58(1):17.
9. **Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, Stowasser M. Does correction of aldosteronism by unilateral adrenalectomy in patients with aldosterone-producing adenoma reduce salt appetite? *Hypertension* 2011;58(1):6.
10. **Pimenta E**, Stowasser M, Gordon RD, Gaddam KK, Oparil S, Calhoun DA. Dietary sodium and aldosterone levels are related to severity of obstructive sleep apnea in patients with resistant hypertension. *Hypertension* 2011;58(1):6.
11. Ahmed AH, Gordon RD, Taylor PJ, Ward G, **Pimenta E**, Stowasser M. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method and route of administration. *Hypertension* 2011;58(1):6.
12. Ahmed AH, Calvird M, Gordon RD, Taylor PJ, Ward G, **Pimenta E**, Stowasser M. Selective serotonin uptake inhibitor antidepressants may interfere with the diagnostic workup of primary aldosteronism. *Hypertension* 2011;58(1):3.
13. **Pimenta E**, Gordon RD, Ahmed AH, Robson D, Cowley D, Kogovsek C, Stowasser M. Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma. 53rd Annual Scientific Meeting of the Endocrine Society of Australia, Sydney, August 2010. Abstract book page 104, abstract#258.
14. **Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Robson D, Kogovsek C, Stowasser M. Correction of aldosterone excess by adrenalectomy reduces salt appetite in patients with aldosterone-producing adenoma. 53rd Annual Scientific Meeting of the Endocrine Society of Australia, Sydney, August 2010. Abstract book page 134, abstract#442.
15. **Pimenta E**, Gaddam KK, Gordon RD, Oparil S, Stowasser M, Calhoun DA. Dietary sodium increases the severity of obstructive sleep apnea in patients with aldosterone excess and resistant hypertension. 53rd Annual Scientific Meeting of the Endocrine Society of Australia, Sydney, August 2010. Abstract book page 131, abstract#436.
16. **Pimenta E**, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, Stowasser M. Cardiac structure is largely influenced by dietary salt in patients with primary aldosteronism but not in patients with normal aldosterone. 53rd Annual Scientific Meeting of the Endocrine Society of Australia, Sydney, August 2010. Abstract book page 131, abstract#437.
17. Ahmed AH, Gordon RD, Taylor PJ, Ward G, **Pimenta E**, Stowasser M. Is the phase of the menstrual cycle important when screening for primary aldosteronism in women, and does renin assay method matter? 53rd Annual Scientific Meeting of the Endocrine Society of Australia, Sydney, August 2010. Abstract book page 102, abstract#254.
18. Ahmed AH, Gordon RD, Taylor PJ, Ward G, **Pimenta E**, Stowasser M. Effect of atenolol on aldosterone/renin ratio calculated by both plasma renin activity and direct renin concentration in healthy male volunteers. 53rd Annual Scientific Meeting of the Endocrine Society of Australia, Sydney, August 2010. Abstract book page 105, abstract#259.
19. Moreno H Jr, Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins LM, Martin, JFV, Yugar-Toledo JC, **Pimenta E**, Calhoun DA. “Uncontrolled and controlled resistant hypertension: really only one hypertensive condition.” *J Hypertens* 2010;28(suppl. A):e573. doi: 10.1097/01.hjh.0000379950.94586.2e.

20. **Pimenta E**, Stowasser M, Leano R, Gordon RD, Cowley D, Marwick TH. “Should treatment for glucocorticoid-suppressible hyperaldosteronism (GSH) be commenced long before hypertension develops, and, if so, which?” *Hypertension* 2010;55(6):1507.
21. **Pimenta E**, Gordon RD, Stowasser M. “Unilateral adrenalectomy improves urinary protein excretion but does not abolish its relationship to sodium excretion in patients with aldosterone-producing adenoma.” *Hypertension* 2010;55(6):1507.
22. **Pimenta E**, Stowasser M, Sharman J, Leano R, Gordon RD, Cowley D, Marwick TH. “Should treatment for glucocorticoid-suppressible hyperaldosteronism (GSH) be commenced long before hypertension develops, and, if so, which?” 52nd Annual Scientific Meeting of the Endocrine Society of Australia, Adelaide, August 2009.
23. Gonzaga CC, Gaddam KK, **Pimenta E**, Pratt-Ubunama MN, Thomas SJ, Oparil S, Calhoun DA, Amodeo C, Sousa AGMR. “Influence of aldosterone excess on blood pressure in patients with resistant hypertension.” *Arq Bras Cardiol* 2009;93(3 suppl. 1):50(*in portuguese*).
24. Gonzaga CC, Gaddam KK, **Pimenta E**, Calhoun DA. “Severity of obstructive sleep apnea dependent upon aldosterone status in subjects with resistant hypertension.” *Circulation* 2008;118:S730.
25. Husain S, Nishizaka MK, **Pimenta E**, Gaddam KK, Oparil S, Calhoun DA. “Similar response to spironolactone in Whites and African-American patients with resistant hypertension.” *Circulation* 2008;118:S887.
26. Husain S, Nishizaka MK, Pratt-Ubunama MN, Gaddam KK, **Pimenta E**, Oparil S, Calhoun DA. “Hyperaldosteronism is equally common in African-American and White patients with resistant hypertension.” *Hypertension* 2008;52(4):e42.
27. Gaddam KK, Corros C, **Pimenta E**, Aban I, Inusah S, Gupta H, Loyd SG, Oparil S, Dell’Italia LJ, Husain A, Calhoun DA. “Hyperaldosteronism causes volume overload cardiac hypertrophy in patients with resistant hypertension.” *Hypertension* 2008;52(4):e76.
28. **Pimenta E**, Gaddam KK, Husain S, Aban A, Oparil S, Calhoun DA. “High dietary salt ingestion increases blood pressure secondary to increases in intravascular volume and vascular resistance in patients with resistant hypertension.” *Hypertension* 2008;52(4):e97.
29. **Pimenta E**, Gaddam KK, Husain S, Oparil S, Calhoun DA. “Dietary salt restriction in patients with resistant hypertension controls blood pressure and improves vascular function” *Arq Bras Cardiol* 2008;91(suppl. 1):27(*in portuguese*).
30. **Pimenta E**, Gaddam KK, Husain S, Oparil S, Calhoun DA. “High-salt diet and aldosterone induces vascular damage and fluid retention in patients with resistant hypertension”, *J Clin Hypertens* 2008;10(5):A162.
31. Husain S, Nishizaka MK, Pratt-Ubunama MN, Oparil S, Gaddam KK, **Pimenta E**, Calhoun DA. “Similar prevalence of hyperaldosteronism in African American and White subjects with resistant hypertension”, *J Clin Hypertens* 2008;10(5):A161.
32. Gaddam KK, Corros C, **Pimenta E**, Husain S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell’Italia LJ, Calhoun DA. “Aldosterone excess increases left and right heart volumes in patients with resistant hypertension – spironolactone but not thiazide diuretics overcome it”, *J Clin Hypertens* 2008;10(5):A95.
33. Gaddam KK, **Pimenta E**, Husain S, Oparil S, Calhoun DA. “Spironolactone improves aldosterone related obstructive sleep apnea in subjects with resistant hypertension”, *J Clin Hypertens* 2008;10(5):A1.
34. **Pimenta E**, Gaddam KK, Pratt-Ubunama MN, Calhoun DA. Continuous positive airway pressure effects on aldosterone secretion in patients with obstructive sleep apnea. *Rev Soc Cardiol Estado de São Paulo* 2008;18(2 supl B):33(*in portuguese*).
35. **Pimenta E**, Gaddam KK, Husain S, Oparil S, Calhoun DA. High-salt diet and aldosterone excess induces vascular damage in patients with resistant hypertension. *Rev Soc Cardiol Estado de São Paulo* 2008;18(2 supl B):78(*in portuguese*).
36. Gaddam KK, Corros C, **Pimenta E**, Husain S, Husain A, Gupta H, Lloyd S, Oparil S, Dell’Italia LJ, Calhoun DA. Aldosterone induces intracardiac volume overload in patients with resistant hypertension – spironolactone but not thiazide diuretics overcomes it. *J Investig Med* 2008;56(1):433.
37. **Pimenta E**, Gaddam KK, Husain S, Oparil S, Calhoun DA. High-salt diet and aldosterone induces vascular damage in patients with resistant hypertension. *J Investig Med* 2008;56(1):425.
38. Husain S, Gaddam KK, **Pimenta E**, Calhoun DA. Similar prevalence of hyperaldosteronism in African American and White subjects with resistant hypertension. *J Investig Med* 2008;56(1):345.

39. Gaddam KK, **Pimenta E**, Inusah S, Gupta H, Lloyd SG, Oparil S, Dell'Italia LJ, Calhoun DA. Spironolactone improves blood pressure and left ventricular hypertrophy in patients with resistant hypertension. *Hypertension* 2007;50(4):e130.
40. **Pimenta E**, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. High dietary salt worsens aldosterone-induced proteinuria in patients with resistant hypertension. *Hypertension* 2007;50(4):e81.
41. Gonzaga CC, Cordeiro Jr. AC, Portela NE, Silva JC, Lotaif L, **Pimenta E**, Sousa MG, Borelli FA, Passarelli Jr O, Piegas L, Amodeo C. Blood pressure difference between arms on 24h ambulatory blood pressure monitoring. *Arq Bras Cardiol* 2007;89(suppl. I):202(in portuguese).
42. Gonzaga CC, Cordeiro Jr. AC, Portela NE, Silva JC, Lotaif L, **Pimenta E**, Sousa MG, Borelli FA, Passarelli Jr O, Piegas L, Amodeo C. Comparative analysis between the prevalence of hypertension diagnosed by office blood pressure and 24hr ambulatory blood pressure monitoring. *Arq Bras Cardiol* 2007;89(suppl. I):175(in portuguese).
43. Monteiro GD, Teixeira RS, Gonzaga CC, Cordeiro Jr. AC, Lotaif L, **Pimenta E**, Sousa MG, Borelli FA, Passarelli Jr O, Piegas L, Amodeo C. Takayasu's arteritis as a cause of secondary hypertension and its complications. *Arq Bras Cardiol* 2007;89(suppl. I):51(in portuguese).
44. Teixeira RS, Monteiro GD, Gonzaga CC, Borelli FA, Sousa MG, Cordeiro Jr. AC, **Pimenta E**, Lotaif L, Passarelli Jr O, Piegas L, Amodeo C. Diagnostisc challenge of phaeochromocytoma in a patient with normal catecholamines. *Arq Bras Cardiol* 2007;89(suppl. I):50(in portuguese).
45. Gonzaga GC, Cordeiro Jr. AC, Portela NE, Silva JC, Lotaif L, **Pimenta E**, Sousa MG, Borelli FA, Passarelli Jr O, Piegas L, Amodeo C. Prevalence of alarm reaction in the 24h ambulatory blood pressure monitoring. *Arq Bras Cardiol* 2007;89(suppl. I):37(in portuguese).
46. **Pimenta E**, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Oparil S, Calhoun DA. Does high office blood pressure represent increased cardiovascular risk in patients with hyperaldosteronism and resistant hypertension? *Arq Bras Cardiol* 2007;89(suppl. I):16(in portuguese).
47. **Pimenta E**, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Oparil S, Calhoun DA. Patients with resistant hypertension and high aldosterone levels present with kidney damage mediated by salt. *Arq Bras Cardiol* 2007;89(suppl. I):2(in portuguese).
48. Gonzaga CC, Salles VA, Sousa MG, Drager LF, Lorenzi Filho G, **Pimenta E**, Borelli FA, Passarelli Jr O, Amodeo C, Piegas L. Correct screening of obstructive sleep apnea syndrome in patients with hypertension. *Rev Soc Cardiol Estado de São Paulo* 2007;17(2 suppl B):26(in portuguese).
49. **Pimenta E**, Pratt-Ubunama MN, Gaddam KK, Nishizaka MK, Oparil S, Calhoun DA. High dietary salt worsens urinary protein excretion in patients with aldosterone excess and resistant hypertension. *J Clin Hypertens* 2007;9(5):A135.
50. Gaddam KK, **Pimenta E**, Pratt-Ubunama MN, Oparil S, Calhoun DA. Resistant hypertension characterized by hyperaldosteronism and refractory intravascular volume expansion. *J Clin Hypertens* 2007;9(5):A132.
51. Gaddam KK, **Pimenta E**, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Aldosterone and cortisol: is there a common stimulus in subjects with resistant hypertension? *J Investig Med* 2007;55(suppl 1):S274.
52. **Pimenta E**, Pratt-Ubunama MN, Gaddam KK, Nishizaka MK, Oparil S, Calhoun DA. Calhoun. Aldosterone excess is associated with true treatment resistance as indicated by sustained ambulatory blood pressure levels and less white-coat effect. *J Investig Med* 2007;55(suppl 1):S276.
53. Corros C, Gaddam KK, Lloyd SG, Pratt-Ubunama MN, **Pimenta E**, Dell'Italia LJ, Calhoun DA, Gupta H. Assesment of left atrial volume in resistant hypertension by cardiac magnetic resonance imaging. *Circulation* 2006;114(18):II-632.
54. Gonzaga CC, Salles VA, Sousa MG, Drager LF, Lorenzi Filho G, **Pimenta E**, Borelli FA, Passarelli Jr O, Amodeo C, Piegas L. Screening of obstructive sleep apnea syndrome in hypertensive patients. *Arq Bras Cardiol* 2006;87 (suppl. I):179(in portuguese).
55. **Pimenta E**, Passarelli Jr O, Borelli FA, Sousa MG, Amato VL, Gun C, Amodeo C, Piegas L. Evaluation of morbidity and mortality after coronary bypass graft surgery in patients with and without metabolic syndrome. *Arq Bras Cardiol* 2006;87 (suppl. I):166(in portuguese).
56. **Pimenta E**, Passarelli Jr O, Borelli FA, Sousa MG, Amodeo C, Piegas L. Does the lack of standardization for diagnostic of metabolic syndrome change its prevalence? *Arq Bras Cardiol* 2006;87 (suppl. I):166(in portuguese).

57. **Pimenta E**, Passarelli Jr O, Borelli FA, Sousa MG, Mascena G, Saleh MH, Amodeo C, Piegas L. Evaluation of inflammatory markers, insulin resistance and endothelial function in patients with metabolic syndrome and normal or increased waist circumference. *Arq Bras Cardiol* 2006;87 (suppl. I):165(in portuguese).
58. Batista Filho MLA, Conceicao CN, Thomaz PG, Pasin F, Henz BD, Haddad VL, Oliveira Jr. JL, **Pimenta E**, Almeida AG, Ribeiro LA. Re-admission at Intensive Care Unit After Coronary Artery Bypass Surgery. *Arq Bras Cardiol* 2006;87 (supl. I):164(in portuguese).
59. **Pimenta E**, Pratt-Ubunama MN, Gaddam KK, Nishizaka MK, Oparil S, Calhoun DA. Calhoun. Dietary Salt Modulates the Hypertensive Effect of High Aldosterone in Subjects with Resistant Hypertension. *Circulation* 2006;114(18):II-534.
60. **Pimenta E**, Pratt-Ubunama MN, Gaddam KK, Nishizaka MK, Oparil S, Calhoun DA. Higher ambulatory blood pressure and less white-coat effect in subjects with hyperaldosteronism and resistant hypertension. *Hypertension* 2006;48:e41.
61. Batista Filho ML, Moura L, Dalegrave C, **Pimenta E**, Pasin F, Lima Jr., Conceicao CN, Lordsleem A, Brandao JC, Morimitsu VS. Analysis of prophylactic and non prophylactic Intra-aortic balloon pump in cardiac surgery and patients with acute myocardial infarction. *Rev Soc Cardiol Estado de São Paulo* 2006;16(2 suppl B):40(in portuguese).
62. **Pimenta E**, Piegas L, Amodeo C, Sousa MG, Borelli FAO, Passarelli Jr O. Prevalence of Metabolic Syndrome in Hypertensive Patients According of Different Criteria. *Rev Soc Cardiol Estado de São Paulo* 2006;16(2 suppl B):85(in portuguese).
63. **Pimenta E**, Piegas L, Amodeo C, Gun C, Amato V, Sousa MG, Borelli FAO, Passarelli Jr O. Can Metabolic Syndrome Influence the Morbidity and Mortality in Patients Underwent Coronary Artery Bypass Grafting? *Rev Soc Cardiol Estado de São Paulo* 2006;16(suppl B):86(in portuguese).
64. **Pimenta E**, Piegas L, Amodeo C, Saleh MH, Veras G, Sousa MG, Borelli FAO, Passarelli Jr O. Comparative Analysis of Endothelial Function, Inflammatory Markers, and Insuline Resistance in Obese and Non Obeses Hipertensive Patients With Metabolic Syndrome. *Rev Soc Cardiol Estado de São Paulo* 2006;16(suppl B):51(in portuguese).
65. Batista Filho MLA, Succi JE, Stolf NAG, Ribeiro LA, Moura L, **Pimenta E**, Aidar JA, Conceicao CN, Daroz LR, Maina LA. Related Factors to Re-admission at Intensive Care Unit After Coronary Artery Bypass Surgery. *Arq Bras Cardiol* 2005;85 (supl.IV):161(in portuguese).
66. **Pimenta E**, Piegas L, Amodeo C, Sousa MG, Borelli FAO, Passarelli Jr O. Is the Waist Circumference Overestimated? The Lack of Relationship Between Waist Circumference and Blood Pressure, Serum Glucose, and Triglycerides. *Arq Bras Cardiol* 2005;85 (suppl.IV):159(in portuguese).
67. Sousa MG, Passarelli Jr O, Borelli FAO, **Pimenta E**, Rosa DP, Umeda II, Carlucci FM, Portela NR, Amodeo C. Prevalence of Different Levels of Hypertension in a Tertiary Service. *Arq Bras Cardiol* 2005;85 (suppl.IV):132(in portuguese).
68. **Pimenta E**, Ramos AIO, Togna DD, Andrade MM, Santos LM, Arnoni AS, Meneghelo ZM, Piegas LS. Incidence and Characteristics of Paravalvular Leak in Mechanical and Biological Valves. *Arq Bras Cardiol* 2005;85 (suppl.IV):40(in portuguese).
69. Dugun RAR, Sousa MG, Borelli FAO, **Pimenta E**, Passarelli Jr O, Gil AO, Amodeo C, Blanco FM. Prevalence of erectile dysfunction in Hypertensive Patients at Public Health Care. *Arq Bras Cardiol* 2005;85 (suppl.IV):35(in portuguese).
70. **Pimenta E**, Ramos AIO, Togna DD, Andrade MM, Santos LM, Arnoni AS, Meneghelo ZM, Piegas LS. Paravalvular Leak: mechanical vs biological valves. *Rev Soc Cardiol Estado de São Paulo* 2005;15(5 suppl B):95(in portuguese).
71. **Pimenta E**, Ramos RF, Gun C, Santos ES, Timerman A, Piegas LS. Renal function development during acute phase of myocardial infarction as prognostic factor in in-hospital and one year outcomes. *Arq Bras Cardiol* 2004;83 (suppl.III):135(in portuguese).
72. **Pimenta E**, Piegas L, Amodeo C, Sousa MG, Borelli FAO, Passarelli Jr O. Paradoxical response of blood pressure and renal function after renal artery reperfusion in hypertensive patients. *Arq Bras Cardiol* 2004;83(suppl.III):123(in portuguese).
73. Batista Filho MLA, Succi JE, Nemes CF, **Pimenta E**, Ribeiro LA, Brunori F, Cauduro P, Albanez ALN, Aidar JA, Oliveira DR. Coronary artery bypass graft surgery in patients older than 80 years. *Arq Bras Cardiol* 2004;83(suppl.III):39(in portuguese).
74. **Pimenta E**, Ramos RF, Gun C, Santos ES, Timerman A, Piegas LS. Is the renal function deterioration during the acute myocardial infarction an independent predictor of prognosis? *Eur Heart J* 2004;25(suppl.):513.

75. Nicolau JC, Ladeira RT , Gagliardi AR, Baracioli LM, **Pimenta ES**, Giraldez RR, Ramires JAF. The role of glycemic level as mortality predictor in acute myocardial infarction. *Eur Heart J* 2003;24(Suppl. 1):174.
76. Marques FRB, Feitosa Filho G, Rodrigues AC, Jardim C, **Pimenta E**, Nishizawa WAT, Betbedé A, Martins MJ, Timerman A. Students profile of ACLS students in FUNCOR training center. *Can J Cardiol* 2003;19(Suppl.A):70A(*in portuguese*).
77. Anti SMA, Silva EC, Silvério J, Alberto LG, Tripodi S, Rosa VP, **Pimenta E**. Hemarthrosis of the Knees Following Streptokinase Therapy for acute myocardial infarction. *Annals of VIII Internacional Congress of Reumatology of South America*.
78. **Pimenta E**, Anti SMA, Pozzan G, Alberto LG, Rosa VP, Szajubok JC, Souza Jr AP. Severe chronic ascites refractory to treatment in lupus erythematosus. *Annals of VIII Internacional Congress of Reumatology of South America*.
79. **Pimenta E**, Pola C, Leão R, Cury Neto S, Pimenta J, Povia R. Acute Coronary Syndrome in Patients Older than 75 years. *Rev Soc Cardiol Estado de São Paulo* 2001;11(suppl B):64(*in portuguese*).
80. Reato LFN, **Pimenta E**, Sebusiani BB, Zanini SF, Poit ML, Banzato RM. Iron Deficiency in Adolescents, presented at Ibero-American Seminary of Adolescence, Belo Horizonte, MG, Brazil, on August, 2000.
81. **Pimenta E**. Initial Approach in Acute Myocardial Infarction, presented at XXIV University Medical Congress of ABC, Santo Andre, SP, Brazil, on August 1999.
82. **Pimenta E**. Splenic epidermoid cyst, presented at XXIII University Medical Congress of ABC, Sao Bernardo do Campo, SP, on August 1998.
83. **Pimenta E**. Surgical resection of ectopic intrathoracic goiter by median sternotomy, presented at XXIII University Medical Congress of ABC, Sao Bernardo do Campo, SP, on August 1998.

LOCAL AND INTERNATIONAL INVITED PRESENTATIONS

1. “Research on Human Tissue and Blood – What Patients, the Law and Researchers Want to Know”, 2014 ARCS Scientific Congress, Sydney, Australia, June 2014.
2. “Partnerships in Medical – Challenges and Opportunities”, 2014 ARCS Scientific Congress, Sydney, Australia, June 2014.
3. “In the pipeline”, 24th Scientific Meeting of the International Society of Hypertension, Sydney, Australia, October 2012.
4. “Optimal Combination Therapy for Hypertension”, GP Update Meeting, 2011 Annual Scientific Meeting of the High Blood Pressure Research Council of Australia, Perth, Australia, December 2011.
5. “Treatment of Resistant Hypertension”, High Blood Pressure Research/American Heart Association and Inter-American Society of Hypertension Scientific Sessions, Orlando, US, September 2011.
6. “Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism, but not in patients with essential hypertension”, British Hypertension Society, Annual Scientific Meeting, Queen’s College, Cambridge, England, September 2011.
7. “Blocking the renin-angiotensin-aldosterone system in coronary artery disease”, Optimizing RAAS Blockade, Australasian Renin Academy, Cardiac Society of Australia and New Zealand, Perth, Australia. August 2011.
8. “Aldosterone and salt: a concert of bad effects”, Queensland Physiology Interest Group, School of Biomedical Sciences, University of Queensland, Brisbane, Australia, June 2011.
9. “What is new in the management of resistant hypertension?”, Cardiovascular Imaging Research Centre, School of Medicine, University of Queensland, Brisbane, Australia, May 2011.
10. “Advances in the treatment of hypertension and the use of combination medicines”, Condamine Medical Centre, Australia, April 2011.
11. “Difficult-to-control hypertension: what are the options?”, The Cardiovascular Symposium 2011, Gold Coast, Australia, April 2011.

12. “The importance of salt on target organ damage induced by aldosterone”, Nephrology Department, Princess Alexandra Hospital, Brisbane, Australia, February 2011.
13. “The importance of salt on target organ damage induced by aldosterone”, Queensland Nephrology Nurses Practitioners, Brisbane, Australia, March 2011.
14. “Aldosterone effects in the target organs: is salt necessary?”, Cardiovascular Imaging Research Centre, School of Medicine, University of Queensland, Brisbane, Australia, April 2010.
15. “Blood pressure, aldosterone and target organ damage: does salt matter?”, Discipline of Medicine Research Day, University of Queensland, Brisbane, Australia, October 2010.
16. “Aldosterone effects in the target organs: is salt essential?” International Society of Hypertension Satellite Meeting, The Pathogenesis of Essential Hypertension: Focus on Salt, Stress and Obesity, Whistler, Canada, September 2010.
17. “Difficult to control hypertension: from doctors to patient’s perspectives”. General Practitioners Academy, Brisbane, Australia, August 2010.
18. “Primary aldosteronism and target organ damage: from diagnosis to treatment”, 13th Annual Conference of Australian Nurse’s Cardiovascular and Hypertension Association (ANCHA), Sydney, Australia, December 2009.
19. “Aldosterone resurgens – The new paradigm of aldosterone – an update”, Inter-american Society of Hypertension, XVIIIth Scientific Sessions, Belo Horizonte, Brazil, August 2009.
20. “Resistant hypertension – definition and prevalence”, Inter-american Society of Hypertension, XVIIIth Scientific Sessions, Belo Horizonte, Brazil, August 2009.
21. “Baroreceptors stimulation for controlling of resistant hypertension”, Inter-american Society of Hypertension, XVIIIth Scientific Sessions, Belo Horizonte, Brazil, August 2009.
22. “Primary Hyperaldosteronism – the latest in diagnosis”, XLVIII International Congress of Mexican Society of Nutrition and Endocrinology, Cancun, Mexico, December, 2008.
23. “Resistant hypertension or resistant patient?”, V Brazilian Symposium of Hypertension of Brazilian Cardiology Society, Natal, Brazil, November 2008.
24. “Primary aldosteronism: from theory to practice”, V Brazilian Symposium of Hypertension of Brazilian Cardiology Society, Natal, Brazil, November 2008.
25. Coordinator of case reports “Resistant hypertension”, V Brazilian Symposium of Hypertension of Brazilian Cardiology Society, Natal, Brazil, November 2008.
26. “Diabetes and hypertension, mechanisms of target organ damage - inflammation”, XV Scientific Sessions of Brazilian Cardiology Society – State of Mato Grosso do Sul Chapter, Campo Grande, Brazil, October 2008.
27. “Heart or arteries? Where does hypertension begins?”, XV Scientific Sessions of Brazilian Cardiology Society – State of Mato Grosso do Sul Chapter, Campo Grande, Brazil, October 2008.
28. “Why do the blood pressure goals are not achieved?”, Symposium of Hypertension of Parana, Curitiba, Brazil, September 2008.
29. “Resistant hypertension and secondary causes: clinical approach”, Symposium of Hypertension of Parana, Curitiba, Brazil, September 2008.
30. “Experience of a hypertension department in a tertiary hospital – Dante Pazzanese Institute of Cardiology”, Symposium of Hypertension of Parana, Curitiba, Brazil, September 2008.
31. Roundtable coordinator, “Continuous medical education: resistant hypertension”, 63° Scientific Sessions of Brazilian Cardiology Society, Curitiba, Brazil, September 2008.
32. “Secondary causes of hypertension: primary aldosteronism”, 63° Scientific Sessions of Brazilian Cardiology Society, Curitiba, Brazil, September 2008.
33. “Analysis of the American Heart Scientific Statement of Resistant Hypertension”, Grand Rounds, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil, September 2008.

34. "Risk stratification: are the guidelines evolving?", XVI Brazilian Congress of Hypertension, Rio de Janeiro, Brazil, August 2008.
35. "Critical analysis of blood pressure goals proposed by international guidelines – is it possible?", 13° Brazilian Multiprofessional Congress of Diabetes, Sao Paulo, Brazil, July 2008.
36. "Hyperaldosteronism", Portugal-Brazil Symposium of Hypertension, Pocone, Brazil, June 2008.
37. Roundtable coordinator, "Secondary hypertension", Portugal-Brazil Symposium of Hypertension, Pocone, Brazil, June 2008.
38. "The patient is resistant to treatment, not the disease", Portugal-Brazil Symposium of Hypertension, Pocone, Brazil, June 2008.
39. "Difficult to control hypertension, co-morbidities and reduction of cardiovascular risk", Portugal-Brazil Symposium of Hypertension, Pocone, Brazil, June 2008.
40. Roundtable coordinator, "Resistant hypertension, comorbidities and reduction of cardiovascular risk", Portugal-Brazil Symposium of Hypertension, Pocone, Brazil, June 2008.
41. "Direct answers for polemic questions: secondary hypertension and resistant hypertension", Portugal-Brazil Symposium of Hypertension, Pocone, Brazil, June 2008.
42. "Drugs that interfere in the blood pressure control", XXV Caribbean and Middle American Congress of Cardiology, Tegucigalpa, Honduras, June, 2008.
43. "Resistant hypertension and aldosterone: treatment and prognostic implications", Grand Rounds, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil, May 2008.
44. "Resistant hypertension – how to approach?", XXIX Scientific Sessions of Brazilian Cardiology Society – State of Sao Paulo Chapter, Sao Paulo, May 2008.
45. "Clinical cases of resistant hypertension", XXIX Scientific Sessions of Brazilian Cardiology Society – State of Sao Paulo Chapter, Sao Paulo, May 2008.
46. Commentator, "Hypertension in 2008: what is happening and what expect in the future", Grand Rounds, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil, April 2008.
47. "Treatment of resistant hypertension", 62° Scientific Sessions of Brazilian Cardiology Society, Sao Paulo, Brazil, September 2007.
48. "Hypertension", Continuous Medical Education of Diabetes and Hypertension for Primary Health Units, Sao Paulo, Brazil, November/December 2005.
49. Roundtable coordinator, "The challenge of correct diagnosis in special situations", II Brazilian Symposium of Hypertension of Brazilian Cardiology Society, Maceio, Brazil, October 2005.
50. "Basic knowledge of cardiac diseases and their implications", Volunteers Association of Adib Jatene Foundation, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil, March 2004.
51. "Cardiovascular emergencies", II Introductory Course for the Cardiology League, Jundiai School of Medicine, Jundiai, Brazil October 2003.
52. "Hemodynamic changes following mechanical ventilation", I Symposium of Mechanical Ventilation, Santo Andre, Brazil. September 2003.